Search Patents
  • Imidazole derivatives and their use for modulating the GABAreceptor complex
    Patent number: 7858649
    Abstract: This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are of the general formula (I) and include any of its stereoisomers, any mixture of its stereoisomers, and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for combating anxiety and related diseases.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: December 28, 2010
    Assignee: Neurosearch A/S
    Inventors: William Dalby Brown, Janus S. Larsen, Lene Teuber, David Tristram Brown, Philip K. Ahring, Naheed Mirza, Elsebet Østergaard Nielsen
  • CYCLOALKYLAMINO ACID DERIVATIVES
    Publication number: 20090227641
    Abstract: The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 7, 2008
    Publication date: September 10, 2009
    Inventors: Samit K. Bhattacharya, Matthew F. Brown, Peter H. Dorff, Susan D. LaGreca, John W. Mickelson, Joseph A. Cornicelli, David L. Brown, Rex Jennings, John K. Walker, Rita Huff, Joseph W. Strohbach, Robert J. Maguire
  • CYCLOALKYLAMINO ACID DERIVATIVES
    Publication number: 20100234435
    Abstract: The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 16, 2010
    Inventors: Samit K. Bhattacharya, Matthew F. Brown, Peter H. Dorff, Susan D. LaGreca, John W. Mickelson, Joseph A. Cornicelli, David L. Brown, Jennings Rex, John K. Walker, Rita Huff, Joseph W. Strohbach, Robert J. Maguire
  • Modulators of sphingosine phosphate receptors
    Patent number: 8481573
    Abstract: Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: July 9, 2013
    Assignee: The Scripps Research Institute
    Inventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
  • Modulators of sphingosine phosphate receptors
    Patent number: 8530503
    Abstract: Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: September 10, 2013
    Assignee: The Scripps Research Institute
    Inventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
  • Modulators of sphingosine phosphate receptors
    Patent number: 8466183
    Abstract: Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: June 18, 2013
    Assignee: The Scripps Research Institute
    Inventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
  • Cycloalkylamino Acid Derivatives
    Publication number: 20100120794
    Abstract: The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 4, 2010
    Publication date: May 13, 2010
    Inventors: Samit Kumar Bhattacharya, Matthew Frank Brown, Peter Hans Dorff, Susan LaGreca